User profiles for Emre Aldinc
Emre AldincVerified email at alnylam.com Cited by 348 |
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Background Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive
disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and …
disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and …
Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis
…, WL Cantley, A Chan, JA Gilbert, D Erbe, E Aldinc… - Neurology, 2021 - AAN Enterprises
Objective To identify changes in the proteome associated with onset and progression of
hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, we …
hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, we …
[HTML][HTML] Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
…, JD Gillmore, P Kale, H Koike, D Danese, E Aldinc… - Neurology and …, 2023 - Springer
Introduction Hereditary transthyretin (ATTRv; v for variant) amyloidosis, also known as
hATTR amyloidosis, is a progressive and fatal disease associated with rapid deterioration of …
hATTR amyloidosis, is a progressive and fatal disease associated with rapid deterioration of …
[HTML][HTML] Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
…, T Coelho, CA Cauquil, C Tard, M Merkel, E Aldinc… - Journal of …, 2020 - Springer
Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease
often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi …
often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi …
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month …
S Ticau, E Aldinc, M Polydefkis, D Adams, T Coelho… - Amyloid, 2024 - Taylor & Francis
Full article: Treatment response and neurofilament light chain levels with long-term patisiran
in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of …
in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of …
[HTML][HTML] Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys
There are no data on physician–patient communication in painful diabetic peripheral
neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient …
neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient …
[HTML][HTML] Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry
…, SM Damrauer, C Tcheandjieu, D Erbe, E Aldinc… - Scientific Reports, 2021 - nature.com
Hereditary transthyretin-mediated (hATTR) amyloidosis is an underdiagnosed, progressively
debilitating disease caused by mutations in the transthyretin (TTR) gene. V122I, a common …
debilitating disease caused by mutations in the transthyretin (TTR) gene. V122I, a common …
[HTML][HTML] Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review
E Aldinc, C Campbell, F Gustafsson… - BMC Musculoskeletal …, 2023 - Springer
Background Hereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses
result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple …
result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple …
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial
D Quan, L Obici, JL Berk, Y Ando, E Aldinc, MT White… - Amyloid, 2023 - Taylor & Francis
Objective Assess how baseline polyneuropathy severity impacts response to patisiran regarding
neurologic impairment and quality of life (QOL) in patients with hereditary transthyretin-…
neurologic impairment and quality of life (QOL) in patients with hereditary transthyretin-…
Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis
…, Y Mochizuki, Y Takahashi, K Takasone, E Aldinc… - Amyloid, 2023 - Taylor & Francis
Hereditary ATTR (ATTRv) amyloidosis is a fatal autosomal dominant disorder in which
variants in the transthyretin (TTR) gene cause systemic deposition of amyloid fibrils. ATTRv …
variants in the transthyretin (TTR) gene cause systemic deposition of amyloid fibrils. ATTRv …